Skip to main content
Premium Trial:

Request an Annual Quote

Variagenics Reports Scant Revenues, Steady Losses for Q3

NEW YORK, Nov. 6-Revenues dwindled and losses remained nearly steady for Variagenics in the third quarter of 2002, the company said today.


For the period ended September 30, 2002, the company reported revenues of $178,000, down from $574,000 in revenues during the equivalent period in 2001.


Losses totaled $6.5 million or 27 cents per share, down slightly from the $6.6 million or 28 cents per share the company registered for the third quarter last year.


R&D spending remained constant at $4.5 million, the same figure that Variagenics reported on September 30, 2001.


As of September 30, the company held $55.7 million in cash, cash equivalents and short-term securities.


During the quarter, Variagenics launched a new pharmacogenomic program to develop diagnostics that will predict patient response to colorectal cancer chemotherapy with 5-fluorouracil.


The company also struck licensing deals with ARUP Laboratoriesand Quest Diagnostics regarding its methylenetetrahydrofolate reductase patent, which covers an allele associated with thromboembolic disease. In addition, Variagenics licensed a separate RNA targeting patent to Renegade Therapeutics in a deal that included up-front fees, milestone payments and royalties on products developed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.